Apertura Gene Therapy

undisclosed funding startup

Announced: Jul 23, 2026
Sector: biotechnology
Investors: 1

Summary

Apertura Gene Therapy said it is participating in a consortium selected to receive funding from ARPA-H’s THRIVE program to develop gene therapies for rare childhood diseases. The consortium will build a Pediatric Epilepsies and Rare CNS gene editing platform using Apertura’s TfR1 CapX capsid.

Investors

Advanced Research Projects Agency for Health (ARPA-H)